Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2013 - 2023)
Amphastar Pharmaceuticals (AMPH) posted quarterly Non-Current Deferred Tax Liability of $201000.0 for Q3 2023, down 16.94% year-over-year from $242000.0 in Q3 2022, and little changed quarter-over-quarter from $201000.0 in Q2 2023.
Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2013 - 2023) Analysis & Trends
Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $201000.0 for Q3 2023.
- In Q3 2023, Non-Current Deferred Tax Liability fell 16.94% year-over-year to $201000.0; the TTM figure through Sep 2023 stood at $201000.0 (down 16.94% YoY), while the FY2022 annual figure was $144000.0, down 73.03% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2023 stood at $201000.0, roughly flat from $201000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $2.9 million in Q3 2021, with the low at $144000.0 in Q4 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $748000.0 (2020), against an average of $724222.2.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability jumped 252.49% in 2021, then slumped 91.66% in 2022.
- Amphastar Pharmaceuticals' Non-Current Deferred Tax Liability stood at $867000.0 in 2019, then dropped by 14.53% to $741000.0 in 2020, then declined by 27.94% to $534000.0 in 2021, then plunged by 73.03% to $144000.0 in 2022, then soared by 39.58% to $201000.0 in 2023.
- Business Quant data shows AMPH's Non-Current Deferred Tax Liability at $201000.0 in Q3 2023, $201000.0 in Q2 2023, and $178000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Amphastar Pharmaceuticals | 945.98 Mn | 655.86 Mn | 93.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 201,000.00 |
| Sep 30, 2023 | 201,000.00 |
| Jun 30, 2023 | 201,000.00 |
| Jun 30, 2023 | 201,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Dec 31, 2022 | 144,000.00 |
| Sep 30, 2022 | 242,000.00 |
| Sep 30, 2022 | 242,000.00 |
| Jun 30, 2022 | 364,000.00 |
| Jun 30, 2022 | 364,000.00 |
| Mar 31, 2022 | 487,000.00 |
| Mar 31, 2022 | 487,000.00 |
| Dec 31, 2021 | 534,000.00 |
| Dec 31, 2021 | 534,000.00 |
| Sep 30, 2021 | 2.90 Mn |
| Sep 30, 2021 | 2.90 Mn |
| Jun 30, 2021 | 765,000.00 |
| Jun 30, 2021 | 765,000.00 |